HLA Class 1 Antigen A26,A34,B71,B62 Antibody from MYBIOSOURCE INC.
Search, find, compare suppliers for anti-HLA Class 1 Antigen A26,A34,B71,B62 antibody, protein, ELISA kits.
| Edit | |
|---|---|
| Antigenic Specificity | HLA Class 1 Antigen A26,A34,B71,B62 |
| Clone | polyclonal |
| Host Species | Mouse |
| Reactive Species | human |
| Isotype | n/a |
| Format | ascites |
| Size | 0.1 mL |
| Concentration | n/a |
| Applications | This antibody has not been tested in methodologies other than Microcytotoxicity Test. Potential applications include Flow Cytometry, Cell Typing, Tissue Staining and Chimerism Studies. |
| Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
| Description | Reacts to HLA Class 1 Antigen-A26,A34,B71,B62. Specificity was determined at a 1:10 dilution by the microcytotoxicity test under standard NIH conditions. The human leukocyte antigen system (HLA) is the name of the major histocompatibility complex (MHC) in humans. The superlocus contains a large number of genes related to immune system function in humans. This group of genes resides on chromosome 6, and encodes cell-surface antigen-presenting proteins and many other genes. The HLA genes are the human versions of the MHC genes that are found in most vertebrates (and thus are the most studied of the MHC genes). The proteins encoded by certain genes are also known as antigens, as a result of their historic discovery as factors in organ transpla |
| Immunogen | Immunogen: HLA Class 1 Antigen-A26, A34, B71, B62. |
| Other Names | n/a |
| Gene, Accession # | n/a |
| Catalog # | MBS601244 |
| Price | $375 |
| Order / More Info | HLA Class 1 Antigen A26,A34,B71,B62 Antibody from MYBIOSOURCE INC. |
| Product Specific References | n/a |
MYBIOSOURCE INC.
MYBIOSOURCE INC.
P.O. Box 153308
San Diego CA 92195-3308
P: 1.858.633.0165
P: 1.888.MBS.0165 (1.888.627.0165) (US & Canada)
F: 1.858.633.0166
sales@mybiosource.com
http://www.MyBioSource.com
Profile of MYBIOSOURCE INC.
Return to Antibodies